Red Blood Cells and Kupffer Cells in Preclinical Models
Red blood cells (RBCs) combined with disease-triggering antigens were found to prevent an autoimmune condition when used beforehand and to reduce symptoms when used afterward. The tolerogenic effects of these peptide-coupled RBCs (pcRBC) relied on specific peptide and cell quantities, with Kupffer cells as necessary for fostering immune tolerance.
- Tags
- #MSResearch
- Most relevant to
- —
Why it matters
This research suggests a novel method for inducing immune tolerance that could be relevant for diseases like multiple sclerosis, which involves unwanted immune responses.
What this does not prove
The study is preclinical and does not establish clinical applicability for MS patients.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-10-07
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceKupffer cells are key mediators of antigen-specific immune tolerance by peptide-coupled red blood cells. ↗DOI: 10.1126/sciadv.aeg6770
Supporting passages (3)
findingsCoupling red blood cells (RBCs) with a cocktail of MS immunodominant peptides is a promising approach to induce antigen-specific immune tolerance in patients.
publication datePublication date: 2026-10-07
limitationsTitle: Kupffer cells are key mediators of antigen-specific immune tolerance by peptide-coupled red blood cells.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.